IL152663A0 - Novel multicyclic compounds and the use thereof - Google Patents
Novel multicyclic compounds and the use thereofInfo
- Publication number
- IL152663A0 IL152663A0 IL15266301A IL15266301A IL152663A0 IL 152663 A0 IL152663 A0 IL 152663A0 IL 15266301 A IL15266301 A IL 15266301A IL 15266301 A IL15266301 A IL 15266301A IL 152663 A0 IL152663 A0 IL 152663A0
- Authority
- IL
- Israel
- Prior art keywords
- novel multicyclic
- multicyclic compounds
- compounds
- novel
- diseases
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 101001005602 Homo sapiens Mitogen-activated protein kinase kinase kinase 11 Proteins 0.000 abstract 1
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 102100025207 Mitogen-activated protein kinase kinase kinase 11 Human genes 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 101710179684 Poly [ADP-ribose] polymerase Proteins 0.000 abstract 1
- 102100023712 Poly [ADP-ribose] polymerase 1 Human genes 0.000 abstract 1
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 abstract 1
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002255 enzymatic effect Effects 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 208000028867 ischemia Diseases 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Psychology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US20294700P | 2000-05-09 | 2000-05-09 | |
| US09/850,858 US7122679B2 (en) | 2000-05-09 | 2001-05-08 | Multicyclic compounds and the use thereof |
| PCT/US2001/014996 WO2001085686A2 (en) | 2000-05-09 | 2001-05-09 | Multicyclic compounds and the use as inhibitors of parp, vegfr2 and mlk3 enzymes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL152663A0 true IL152663A0 (en) | 2003-06-24 |
Family
ID=26898160
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL15266301A IL152663A0 (en) | 2000-05-09 | 2001-05-09 | Novel multicyclic compounds and the use thereof |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US7122679B2 (cs) |
| EP (3) | EP2050750B1 (cs) |
| JP (1) | JP5156150B2 (cs) |
| KR (1) | KR100832602B1 (cs) |
| CN (2) | CN100554268C (cs) |
| AT (3) | ATE315039T1 (cs) |
| AU (1) | AU6132701A (cs) |
| BG (1) | BG66036B1 (cs) |
| BR (1) | BR0110993A (cs) |
| CA (1) | CA2409758A1 (cs) |
| CY (1) | CY1108722T1 (cs) |
| CZ (2) | CZ305350B6 (cs) |
| DE (3) | DE60143140D1 (cs) |
| DK (1) | DK1754707T3 (cs) |
| EA (1) | EA007868B1 (cs) |
| ES (2) | ES2315789T3 (cs) |
| HU (1) | HU229448B1 (cs) |
| IL (1) | IL152663A0 (cs) |
| MX (1) | MXPA02010977A (cs) |
| NO (1) | NO324256B1 (cs) |
| NZ (1) | NZ522539A (cs) |
| PL (1) | PL226805B1 (cs) |
| PT (1) | PT1754707E (cs) |
| SK (1) | SK287591B6 (cs) |
| UA (1) | UA73773C2 (cs) |
| WO (1) | WO2001085686A2 (cs) |
| ZA (1) | ZA200209065B (cs) |
Families Citing this family (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6811992B1 (en) | 1998-05-14 | 2004-11-02 | Ya Fang Liu | Method for identifying MLK inhibitors for the treatment of neurological conditions |
| US6531464B1 (en) | 1999-12-07 | 2003-03-11 | Inotek Pharmaceutical Corporation | Methods for the treatment of neurodegenerative disorders using substituted phenanthridinone derivatives |
| US6476048B1 (en) | 1999-12-07 | 2002-11-05 | Inotek Pharamaceuticals Corporation | Substituted phenanthridinones and methods of use thereof |
| US20060276497A1 (en) * | 2000-05-09 | 2006-12-07 | Cephalon, Inc. | Novel multicyclic compounds and the use thereof |
| US7151102B2 (en) | 2000-10-30 | 2006-12-19 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
| WO2003051883A1 (fr) * | 2001-12-18 | 2003-06-26 | Kyowa Hakko Kogyo Co., Ltd. | Derive d'indole |
| CA2483496A1 (en) * | 2002-04-26 | 2003-11-06 | Warner-Lambert Company Llc | Inhibitors of checkpoint kinases (wee1 and chk1) |
| US7094798B1 (en) | 2002-04-26 | 2006-08-22 | Pfizer Inc | Inhibitors of checkpoint kinases (Wee1 and Chk1) |
| JP4500161B2 (ja) | 2002-04-30 | 2010-07-14 | クドス ファーマシューティカルズ リミテッド | フタラジノン誘導体 |
| GB0305681D0 (en) | 2003-03-12 | 2003-04-16 | Kudos Pharm Ltd | Phthalazinone derivatives |
| US7449464B2 (en) | 2003-03-12 | 2008-11-11 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
| US7511065B2 (en) | 2003-11-12 | 2009-03-31 | Eli Lilly And Company | Mixed lineage kinase modulators |
| CN1905864B (zh) * | 2003-12-01 | 2011-04-06 | 库多斯药物有限公司 | 用于治疗癌症的dna损伤修复抑制剂 |
| CN102107008B (zh) * | 2003-12-01 | 2013-04-03 | 库多斯药物有限公司 | 用于治疗癌症的dna损伤修复抑制剂 |
| PE20060285A1 (es) * | 2004-03-30 | 2006-05-08 | Aventis Pharma Inc | Piridonas sustituidas como inhibidores de pol(adp-ribosa)-polimerasa (parp) |
| CN1980917B (zh) * | 2004-05-03 | 2014-02-12 | 詹森药业有限公司 | 作为选择性雄激素受体调节剂（sarms）的新的吲哚衍生物 |
| GB0419072D0 (en) | 2004-08-26 | 2004-09-29 | Kudos Pharm Ltd | Phthalazinone derivatives |
| EP1841771A4 (en) | 2005-01-19 | 2008-09-24 | Mgi Gp Inc | COMPOUNDS OF DIAZABENZO [DE] ANTHRACENE-3-ONE AND USE IN INHIBITION OF PARP |
| NZ587586A (en) * | 2005-07-18 | 2012-04-27 | Bipar Sciences Inc | Treatment of cancer |
| DE602006019882D1 (de) * | 2005-09-02 | 2011-03-10 | Otsuka Pharma Co Ltd | Verfahren für die zubereitung von benzazepinverbindungen oder salzen daraus |
| ATE536349T1 (de) * | 2005-09-29 | 2011-12-15 | Abbott Lab | In der 2-stellung durch phenyl substituierte 1h- benzimidazol-4-carbonsäureamide sind wirksame parp-inhibitoren |
| GB0521373D0 (en) | 2005-10-20 | 2005-11-30 | Kudos Pharm Ltd | Pthalazinone derivatives |
| US20100279327A1 (en) * | 2006-06-12 | 2010-11-04 | Bipar Sciences, Inc. | Method of treating diseases with parp inhibitors |
| AU2007292306A1 (en) * | 2006-09-05 | 2008-03-13 | Bipar Sciences, Inc. | Inhibition of fatty acid synthesis by PARP inhibitors and methods of treatment thereof |
| EP2059802A4 (en) * | 2006-09-05 | 2010-09-08 | Bipar Sciences Inc | METHODS FOR DESIGNING PARP INHIBITORS AND USES THEREOF |
| WO2008030883A2 (en) * | 2006-09-05 | 2008-03-13 | Bipar Sciences, Inc. | Treatment of cancer |
| TWI404716B (zh) | 2006-10-17 | 2013-08-11 | Kudos Pharm Ltd | 酞嗪酮（ｐｈｔｈａｌａｚｉｎｏｎｅ）衍生物 |
| WO2008063644A1 (en) * | 2006-11-20 | 2008-05-29 | Cephalon, Inc. | Method of radio-sensitizing tumors using a radio-sensitizing agent |
| US9061009B2 (en) * | 2007-06-08 | 2015-06-23 | University Of Massachusetts | Mixed lineage kinases and metabolic disorders |
| KR20100059950A (ko) | 2007-09-14 | 2010-06-04 | 아스트라제네카 아베 | 프탈라지논 유도체 |
| EP2209375B1 (en) | 2007-10-03 | 2014-08-27 | Eisai Inc. | Parp inhibitor compounds, compositions and methods of use |
| EP2211854A4 (en) * | 2007-10-19 | 2011-01-12 | Bipar Sciences Inc | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER USING BENZOPYRONE-TYPE PARP INHIBITORS |
| KR20100102607A (ko) * | 2007-11-12 | 2010-09-24 | 바이파 사이언스 인코포레이티드 | Ｐａｒｐ 억제제를 단독으로 사용하거나 항종양제와 병용하여 자궁암 및 난소암을 치료하는 방법 |
| CA2705537A1 (en) * | 2007-11-12 | 2009-05-22 | Bipar Sciences, Inc. | Treatment of breast cancer with a parp inhibitor alone or in combination with anti-tumor agents |
| CA2708157A1 (en) * | 2007-12-07 | 2009-06-11 | Bipar Sciences, Inc. | Treatment of cancer with combinations of topoisomerase inhibitors and parp inhibitors |
| AR070221A1 (es) | 2008-01-23 | 2010-03-25 | Astrazeneca Ab | Derivados de ftalazinona inhibidores de polimerasas, composiciones farmaceuticas que los contienen y usos de los mismos para prevenir y/o tratar tumores cancerigenos,lesiones isquemicas y otras enfermedades asociadas. |
| US20090275608A1 (en) * | 2008-02-04 | 2009-11-05 | Bipar Sciences, Inc. | Methods of diagnosing and treating parp-mediated diseases |
| JP2010006717A (ja) * | 2008-06-24 | 2010-01-14 | Kyorin Pharmaceut Co Ltd | ジヒドロチエノ［２，３−ｅ］インダゾール化合物 |
| PT2346495T (pt) | 2008-10-07 | 2016-11-11 | Astrazeneca Uk Ltd | Formulação farmacêutica 514 |
| WO2010082813A1 (en) | 2009-01-13 | 2010-07-22 | Academisch Medisch Centrum Bij De Universiteit Van Amsterdam | Method of treating cancer |
| EA020756B1 (ru) | 2009-08-26 | 2015-01-30 | Сефалон, Инк. | Новые формы полициклического соединения |
| WO2011058367A2 (en) | 2009-11-13 | 2011-05-19 | Astrazeneca Ab | Diagnostic test for predicting responsiveness to treatment with poly(adp-ribose) polymerase (parp) inhibitor |
| WO2011077502A1 (ja) * | 2009-12-21 | 2011-06-30 | 杏林製薬株式会社 | ジヒドロチエノ［２，３－ｅ］インダゾール化合物 |
| KR101528688B1 (ko) | 2010-12-02 | 2015-06-12 | 상하이 드 노보 파마테크 컴퍼니 리미티드 | 헤테로사이클릭 유도체, 이의 제조 방법 및 이의 의학적 용도 |
| US9771325B2 (en) | 2014-02-14 | 2017-09-26 | Council Of Scientific & Industrial Research | Tricyclic compounds and preparation thereof |
| WO2015121876A1 (en) * | 2014-02-14 | 2015-08-20 | Council Of Scientific & Industrial Research | Novel tricyclic compounds and preparation thereof |
| KR20170088894A (ko) | 2014-11-26 | 2017-08-02 | 세파론, 인코포레이티드 | Parp 억제제의 결정질 형태 |
| TW201702218A (zh) | 2014-12-12 | 2017-01-16 | 美國杰克森實驗室 | 關於治療癌症、自體免疫疾病及神經退化性疾病之組合物及方法 |
| PT3325623T (pt) | 2015-07-23 | 2019-09-04 | Inst Curie | Utilização de uma combinação de molécula dbait e de inibidores de parp para o tratamento do cancro |
| GB201519573D0 (en) | 2015-11-05 | 2015-12-23 | King S College London | Combination |
| US10722484B2 (en) | 2016-03-09 | 2020-07-28 | K-Gen, Inc. | Methods of cancer treatment |
| WO2018022851A1 (en) | 2016-07-28 | 2018-02-01 | Mitobridge, Inc. | Methods of treating acute kidney injury |
| EP3534957A1 (en) | 2016-11-02 | 2019-09-11 | Immunogen, Inc. | Combination treatment with antibody-drug conjugates and parp inhibitors |
| WO2018162439A1 (en) | 2017-03-08 | 2018-09-13 | Onxeo | New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule |
| EP3615026B1 (en) | 2017-04-28 | 2021-03-03 | Akribes Biomedical GmbH | A parp inhibitor in combination with a glucocorticoid and/or ascorbic acid and/or a protein growth factor for the treatment of impaired wound healing |
| JP7534218B2 (ja) | 2018-03-13 | 2024-08-14 | ヴァレリオ・セラピューティクス | がんの治療における獲得耐性に対抗するｄｂａｉｔ分子 |
| WO2019195658A1 (en) | 2018-04-05 | 2019-10-10 | Dana-Farber Cancer Institute, Inc. | Sting levels as a biomarker for cancer immunotherapy |
| WO2021041532A1 (en) | 2019-08-26 | 2021-03-04 | Dana-Farber Cancer Institute, Inc. | Use of heparin to promote type 1 interferon signaling |
| GB201913030D0 (en) | 2019-09-10 | 2019-10-23 | Francis Crick Institute Ltd | Treatment of hr deficient cancer |
| CN110862396B (zh) * | 2019-11-29 | 2021-06-04 | 浙江工业大学 | 一种吡咯并[3,4-c]咔唑-1,3(2H，6H)-二酮类化合物的合成方法 |
| KR102572704B1 (ko) | 2019-12-16 | 2023-08-30 | 한국화학연구원 | 신규한 피리미딘 유도체 및 이의 용도 |
| WO2021125803A1 (ko) | 2019-12-16 | 2021-06-24 | 한국화학연구원 | 신규한 피리미딘 유도체 및 이의 용도 |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| CN113636970B (zh) * | 2021-09-13 | 2023-05-23 | 河北康泰药业有限公司 | 一种异吲哚酮的化合物、制备方法及其应用 |
| KR20230155351A (ko) | 2022-05-03 | 2023-11-10 | 한국화학연구원 | 5-클로로-2,4-다이아미노피리미딘을 포함하는 키나아제 억제 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물 |
| KR20240156074A (ko) | 2023-04-21 | 2024-10-29 | (주)엠디바이오팜 | Hpk1 및 mlk3 저해제 및 이를 함유하는 항암용 조성물 |
| WO2024261243A1 (en) | 2023-06-21 | 2024-12-26 | Hemispherian As | Combination comprising a deoxycytidine derivative and a parp inhibitor for use in a method of treating hr proficient cancer |
| KR20250041906A (ko) | 2023-09-19 | 2025-03-26 | (주)엠디바이오팜 | Hpk1 및 mlk3 저해 활성을 갖는 신규한 화합물 및 이를 함유하는 항암용 조성물 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5177075A (en) | 1988-08-19 | 1993-01-05 | Warner-Lambert Company | Substituted dihydroisoquinolinones and related compounds as potentiators of the lethal effects of radiation and certain chemotherapeutic agents; selected compounds, analogs and process |
| DE3833008A1 (de) * | 1988-09-29 | 1990-04-05 | Goedecke Ag | Pyrrolocarbozol-derivate, verfahren zu deren herstellung und deren verwendung als arzneimittel |
| GB2239013B (en) | 1989-11-01 | 1993-06-02 | Toyama Chemical Co Ltd | Novel isoindole derivatives and salts thereof,processes for producing the same and antitumor agent comprising the same |
| JP3025536B2 (ja) | 1990-12-27 | 2000-03-27 | 富山化学工業株式会社 | 新規なカルバゾール誘導体およびその塩 |
| WO1992014453A1 (en) | 1991-02-26 | 1992-09-03 | Arc 1, Inc. | Compositions and methods of treatment of sympathetically maintained pain |
| US5298506A (en) * | 1992-05-08 | 1994-03-29 | Brigham And Women's Hospital | Use of guanylate cyclase inhibitors in the treatment of shock |
| DE4217964A1 (de) * | 1992-05-30 | 1993-12-02 | Goedecke Ag | Indolocarbazol-Imide und deren Verwendung |
| GB9319297D0 (en) * | 1993-09-17 | 1993-11-03 | Wellcome Found | Indole derivatives |
| US5587384A (en) | 1994-02-04 | 1996-12-24 | The Johns Hopkins University | Inhibitors of poly(ADP-ribose) synthetase and use thereof to treat NMDA neurotoxicity |
| US5599808A (en) * | 1994-02-18 | 1997-02-04 | Cephalon, Inc. | Aqueous indolocarbazole solutions |
| GB9404485D0 (en) | 1994-03-09 | 1994-04-20 | Cancer Res Campaign Tech | Benzamide analogues |
| ES2123873T3 (es) * | 1994-08-04 | 1999-01-16 | Hoffmann La Roche | Pirrolocarbazol. |
| US5705511A (en) * | 1994-10-14 | 1998-01-06 | Cephalon, Inc. | Fused pyrrolocarbazoles |
| WO1996028447A1 (fr) | 1995-03-09 | 1996-09-19 | Kyowa Hakko Kogyo Co., Ltd. | Derives de pyrrolocarbazole |
| CN1097460C (zh) * | 1996-08-22 | 2003-01-01 | 布里斯托尔-迈尔斯斯奎布公司 | 吲哚并吡咯并咔唑的细胞毒的氨基糖及相关的糖衍生物 |
| AU4136197A (en) | 1996-09-09 | 1998-03-26 | Kyowa Hakko Kogyo Co. Ltd. | Pyrrolocarbazole derivatives |
| WO1999008680A1 (en) | 1997-08-15 | 1999-02-25 | The Johns Hopkins University | Method of using selective parp inhibitors to prevent or treat neurotoxicity |
| US6635642B1 (en) | 1997-09-03 | 2003-10-21 | Guilford Pharmaceuticals Inc. | PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same |
| US20020022636A1 (en) | 1997-09-03 | 2002-02-21 | Jia-He Li | Oxo-substituted compounds, process of making, and compositions and methods for inhibiting parp activity |
| US6197785B1 (en) | 1997-09-03 | 2001-03-06 | Guilford Pharmaceuticals Inc. | Alkoxy-substituted compounds, methods, and compositions for inhibiting PARP activity |
| US20020028813A1 (en) | 1997-09-03 | 2002-03-07 | Paul F. Jackson | Thioalkyl compounds, methods, and compositions for inhibiting parp activity |
| US6514983B1 (en) | 1997-09-03 | 2003-02-04 | Guilford Pharmaceuticals Inc. | Compounds, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage |
| WO1999011622A1 (en) | 1997-09-03 | 1999-03-11 | Guilford Pharmaceuticals Inc. | Amino-substituted compounds, methods, and compositions for inhibiting parp activity |
| AU9298198A (en) | 1997-09-03 | 1999-03-22 | Guilford Pharmaceuticals Inc. | Di-n-heterocyclic compounds, methods, and compositions for inhibiting parp activity |
| AU748887B2 (en) | 1998-02-12 | 2002-06-13 | Myriad Genetics, Inc. | Beta-sheet mimetics and methods relating to the use thereof |
| JP2002506868A (ja) | 1998-03-13 | 2002-03-05 | ザ ユニバーシティー オブ ブリティッシュ コロンビア | 癌治療において用いるためのグラニュラチミド誘導体 |
| AU9297998A (en) | 1998-05-15 | 1999-12-06 | Guilford Pharmaceuticals Inc. | Carboxamide compounds, compositions, and methods for inhibiting parp activity |
| WO1999059975A1 (en) | 1998-05-15 | 1999-11-25 | Guilford Pharmaceuticals Inc. | Fused tricyclic compounds which inhibit parp activity |
| US6063803A (en) * | 1998-06-16 | 2000-05-16 | Ortho-Mcneil Pharmaceutical, Inc. | Octahydropyrrolo-[3,4-c]carbazoles useful as analgesic agents |
| HUP0103079A3 (en) * | 1998-08-26 | 2004-03-01 | Cephalon Inc | Modulating multiple lineage kinase proteins |
| US6841567B1 (en) * | 1999-02-12 | 2005-01-11 | Cephalon, Inc. | Cyclic substituted fused pyrrolocarbazoles and isoindolones |
| US6399780B1 (en) * | 1999-08-20 | 2002-06-04 | Cephalon, Inc. | Isomeric fused pyrrolocarbazoles and isoindolones |
-
2001
- 2001-05-08 US US09/850,858 patent/US7122679B2/en not_active Expired - Lifetime
- 2001-05-09 PT PT05076862T patent/PT1754707E/pt unknown
- 2001-05-09 CN CNB018120695A patent/CN100554268C/zh not_active Expired - Fee Related
- 2001-05-09 AT AT01935215T patent/ATE315039T1/de active
- 2001-05-09 EP EP08075834A patent/EP2050750B1/en not_active Expired - Lifetime
- 2001-05-09 DK DK05076862T patent/DK1754707T3/da active
- 2001-05-09 ES ES05076862T patent/ES2315789T3/es not_active Expired - Lifetime
- 2001-05-09 PL PL363167A patent/PL226805B1/pl unknown
- 2001-05-09 MX MXPA02010977A patent/MXPA02010977A/es active IP Right Grant
- 2001-05-09 DE DE60143140T patent/DE60143140D1/de not_active Expired - Lifetime
- 2001-05-09 EA EA200201183A patent/EA007868B1/ru not_active IP Right Cessation
- 2001-05-09 NZ NZ522539A patent/NZ522539A/en not_active IP Right Cessation
- 2001-05-09 CZ CZ2011-756A patent/CZ305350B6/cs not_active IP Right Cessation
- 2001-05-09 DE DE60116485T patent/DE60116485T2/de not_active Expired - Lifetime
- 2001-05-09 IL IL15266301A patent/IL152663A0/xx not_active IP Right Cessation
- 2001-05-09 WO PCT/US2001/014996 patent/WO2001085686A2/en active Application Filing
- 2001-05-09 AT AT08075834T patent/ATE482215T1/de not_active IP Right Cessation
- 2001-05-09 EP EP01935215A patent/EP1294725B1/en not_active Expired - Lifetime
- 2001-05-09 ES ES01935215T patent/ES2256238T3/es not_active Expired - Lifetime
- 2001-05-09 BR BR0110993-6A patent/BR0110993A/pt active Search and Examination
- 2001-05-09 JP JP2001582287A patent/JP5156150B2/ja not_active Expired - Fee Related
- 2001-05-09 AU AU6132701A patent/AU6132701A/xx active Pending
- 2001-05-09 EP EP05076862A patent/EP1754707B1/en not_active Expired - Lifetime
- 2001-05-09 AT AT05076862T patent/ATE411997T1/de active
- 2001-05-09 DE DE60136305T patent/DE60136305D1/de not_active Expired - Lifetime
- 2001-05-09 HU HU0302385A patent/HU229448B1/hu not_active IP Right Cessation
- 2001-05-09 SK SK1580-2002A patent/SK287591B6/sk not_active IP Right Cessation
- 2001-05-09 KR KR1020027015062A patent/KR100832602B1/ko not_active Expired - Fee Related
- 2001-05-09 CN CN2009101354977A patent/CN101560213B/zh not_active Expired - Fee Related
- 2001-05-09 CA CA002409758A patent/CA2409758A1/en not_active Abandoned
- 2001-05-09 CZ CZ2002-3679A patent/CZ304911B6/cs not_active IP Right Cessation
- 2001-09-05 UA UA2002129794A patent/UA73773C2/uk unknown
-
2002
- 2002-11-07 ZA ZA200209065A patent/ZA200209065B/en unknown
- 2002-11-08 NO NO20025376A patent/NO324256B1/no not_active IP Right Cessation
- 2002-12-05 BG BG107355A patent/BG66036B1/bg unknown
-
2009
- 2009-01-16 CY CY20091100056T patent/CY1108722T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU6132701A (en) | Novel multicyclic compounds and the use thereof | |
| PT966447E (pt) | Moleculas pequenas uteis no tratamento de doencas inflamatorias | |
| WO2007149451A3 (en) | Cycloalkanopyrrolocarbazole derivatives and the use thereof as parp, vegfr2 and mlk3 inhibitors | |
| MY135766A (en) | Quinolinones and naphthyridinones for treating inflammatory diseases | |
| WO2000038717A3 (en) | Use of a matrix metalloproteinase inhibitor and radiation as a combined treatment of neoplasia | |
| MY155218A (en) | Small molecules useful in the treatment of inflammatory disease | |
| WO2004093803A3 (en) | Photochemotherapeutic compounds for use in treatment of pin1-associated states | |
| ATE357272T1 (de) | Verwendung von phthalazin-derivaten zur behandlung neurodegenerativer krankheiten | |
| PL345560A1 (en) | Benzimidazole derivatives as modulators of ige | |
| WO2005016946A3 (en) | Platinum complexes for the treatment of tumors | |
| WO2003032916A3 (en) | Organosulfur inhibitors of tyrosine phosphatases | |
| NO20014560L (no) | Quinasoliner og terapautisk anvendelse derav | |
| EE200300559A (et) | Osteopontiini kasutamine neuroloogiliste haigusteraviks ja/või vältimiseks | |
| NZ333232A (en) | Use of p-aminophenol derivatives (paracetamol) to treat neurodegenerative disease | |
| TR200103125T2 (tr) | Otizmin iyileştirilmesinde kullanıma yönelik antikonvülsan türevleri. | |
| AU1278600A (en) | Novel therapeutic application of nicergoline | |
| NO20005548D0 (no) | Mykobakterieinhibitorer | |
| EP1372639A4 (en) | TREATMENT AGENT FOR BLADDER IRRITATION SYMPTOMS ACCOMPANIED WITH BENIGN PROSTATIC HYPERPLASIA | |
| ID30458A (id) | Osanetan dalam pengobatan gangguan jiwa | |
| EE200200670A (et) | S-metüüldihüdroziprasidoon psühhiaatriliste ja silmahaiguste raviks | |
| DE60133563D1 (de) | Külen | |
| TR200003084T2 (tr) | Paroxetine askorbat | |
| NO20030762D0 (no) | Forbedret spesifisitet i behandling av sykdommer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| MM9K | Patent not in force due to non-payment of renewal fees |